Literature DB >> 3733379

Phase II trial of 4'-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer.

T Braich, F R Ahmann, H S Garewal, A Robertone, S E Salmon.   

Abstract

Fifteen patients with hormone resistant advanced prostate cancer were treated with anthracycline analog 4'-deoxydoxorubicin (Esorubicin). No patient had objective evidence of tumor regression. Six patients (40%) were classified using the National Prostatic Cancer Project criteria as having stable disease after two courses of therapy. Treatment was associated with significant hematologic toxicity with 50% of patients experiencing grade III or IV neutropenia. Clinical cardiac toxicity was not observed. Further trials of 4'-deoxydoxorubicin do not appear to be warranted in advanced prostate cancer.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3733379     DOI： 10.1007/bf00194602

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  9 in total

1.  Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone.

Authors:  G P Murphy; S Beckley; M F Brady; T M Chu; J B deKernion; C Dhabuwala; J F Gaeta; R P Gibbons; S A Loening; C F McKiel; D G McLeod; J E Pontes; G R Prout; P T Scardino; J U Schlegel; J D Schmidt; W W Scott; N H Slack; M S Soloway
Journal:  Cancer       Date:  1983-04-01       Impact factor: 6.860

Review 2.  The chemotherapy of prostatic adenocarcinoma.

Authors:  F M Torti; S K Carter
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

3.  Experimental evaluation of anthracycline analogs.

Authors:  A M Casazza
Journal:  Cancer Treat Rep       Date:  1979-05

4.  Antitumor activity of esorubicin in human tumor clonogenic assay with comparisons to doxorubicin.

Authors:  S E Salmon; L Young; B Soehnlen; R Liu
Journal:  J Clin Oncol       Date:  1984-04       Impact factor: 44.544

5.  The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer.

Authors:  N H Slack; A Mittelman; M F Brady; G P Murphy
Journal:  Cancer       Date:  1980-12-01       Impact factor: 6.860

6.  Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy.

Authors:  D F Paulson; W R Berry; E B Cox; A Walker; J Laszlo
Journal:  J Natl Cancer Inst       Date:  1979-09       Impact factor: 13.506

7.  Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate.

Authors:  W R Berry; J Laszlo; E Cox; A Walker; D Paulson
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

8.  Phase I trial of esorubicin (4'deoxydoxorubicin).

Authors:  H S Garewal; A Robertone; S E Salmon; S E Jones; D S Alberts; R Brooks
Journal:  J Clin Oncol       Date:  1984-09       Impact factor: 44.544

9.  A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer.

Authors:  D L Citrin; T F Hogan
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860
  9 in total
  4 in total

1.  Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.

Authors:  Q S Ringenberg; K J Propert; H B Muss; R B Weiss; R L Schilsky; C Modeas; M C Perry; L Norton; M Green
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.

Authors:  W P McGuire; J A Blessing; M L Berman
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

Review 3.  Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature.

Authors:  L F Diehl; A Banks; W Carter; M A Klein; H B Muss; R B Weiss
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  W P McGuire; J A Blessing; E Yordan; J Beecham
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.